Onconova Therapeutics Stock Forecast, Price & News

Onconova Therapeutics (NASDAQ:ONTX) Frequently Asked Questions

Is Onconova Therapeutics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Onconova Therapeutics stock.
View analyst ratings for Onconova Therapeutics or view top-rated stocks.

How has Onconova Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Onconova Therapeutics' stock was trading at $5.40 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ONTX shares have decreased by 41.3% and is now trading at $3.17.
View which stocks have been most impacted by COVID-19.

Are investors shorting Onconova Therapeutics?

Onconova Therapeutics saw a drop in short interest in the month of October. As of October 29th, there was short interest totaling 438,200 shares, a drop of 52.6% from the October 14th total of 923,500 shares. Based on an average daily trading volume, of 1,930,000 shares, the days-to-cover ratio is presently 0.2 days.
View Onconova Therapeutics' Short Interest.

When is Onconova Therapeutics' next earnings date?

Onconova Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Onconova Therapeutics.

How were Onconova Therapeutics' earnings last quarter?

Onconova Therapeutics, Inc. (NASDAQ:ONTX) issued its quarterly earnings data on Thursday, November, 11th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.33) by $0.11. Onconova Therapeutics had a negative net margin of 8,294.27% and a negative trailing twelve-month return on equity of 74.01%. During the same period last year, the firm earned ($0.45) earnings per share.
View Onconova Therapeutics' earnings history.

When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?

Onconova Therapeutics shares reverse split before market open on Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 20th 2021. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for ONTX?

2 analysts have issued 12-month price targets for Onconova Therapeutics' shares. Their forecasts range from $11.00 to $12.00. On average, they anticipate Onconova Therapeutics' stock price to reach $11.50 in the next twelve months. This suggests a possible upside of 262.8% from the stock's current price.
View analysts' price targets for Onconova Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Onconova Therapeutics' key executives?

Onconova Therapeutics' management team includes the following people:

• Steven M. Fruchtman, President, Chief Executive Officer & Director (LinkedIn Profile)
• Mark P. Guerin, Chief Financial Officer
• Matthew Parris, Vice President-Clinical Operations
• Mark Stephen Gelder, Chief Medical Officer
• Abraham Noah Oler, SVP-Corporate Development & General Counsel (LinkedIn Profile)

Who are some of Onconova Therapeutics' key competitors?

Some companies that are related to Onconova Therapeutics include Checkpoint Therapeutics (CKPT), Theratechnologies (THERF), CymaBay Therapeutics (CBAY), Connect Biopharma (CNTB), Aquestive Therapeutics (AQST), UroGen Pharma (URGN), Pieris Pharmaceuticals (PIRS), XOMA (XOMA), Syros Pharmaceuticals (SYRS), Citius Pharmaceuticals (CTXR), TherapeuticsMD (TXMD), GX Acquisition (GXGX), Athersys (ATHX), CTI BioPharma (CTIC) and Sensei Biotherapeutics (SNSE).
View all of ONTX's competitors.

What other stocks do shareholders of Onconova Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Outlook Therapeutics (OTLK) and Actinium Pharmaceuticals (ATNM).

What is Onconova Therapeutics' stock symbol?

Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."

Who are Onconova Therapeutics' major shareholders?

Onconova Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include GSA Capital Partners LLP (1.16%), Geode Capital Management LLC (0.85%), Pura Vida Investments LLC (0.72%), CVI Holdings LLC (0.62%), Morgan Stanley (0.22%) and Citadel Advisors LLC (0.00%). Company insiders that own Onconova Therapeutics stock include Abraham N Oler, Abraham N Oler, E Premkumar Reddy, James J Marino, Jerome Groopman, Mark Patrick Guerin and Steven M Fruchtman.
View institutional ownership trends for Onconova Therapeutics.

Which institutional investors are selling Onconova Therapeutics stock?

ONTX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, and Dimensional Fund Advisors LP.
View insider buying and selling activity for Onconova Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Onconova Therapeutics stock?

ONTX stock was bought by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Pura Vida Investments LLC, CVI Holdings LLC, Geode Capital Management LLC, Citadel Advisors LLC, and Goldman Sachs Group Inc.. Company insiders that have bought Onconova Therapeutics stock in the last two years include Abraham N Oler, James J Marino, Jerome Groopman, Mark Patrick Guerin, and Steven M Fruchtman.
View insider buying and selling activity for Onconova Therapeutics or or view top insider-buying stocks.

How do I buy shares of Onconova Therapeutics?

Shares of ONTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Onconova Therapeutics' stock price today?

One share of ONTX stock can currently be purchased for approximately $3.17.

How much money does Onconova Therapeutics make?

Onconova Therapeutics has a market capitalization of $65.88 million and generates $230 thousand in revenue each year. The biopharmaceutical company earns $-25.16 million in net income (profit) each year or ($1.2396) on an earnings per share basis.

How many employees does Onconova Therapeutics have?

Onconova Therapeutics employs 12 workers across the globe.

What is Onconova Therapeutics' official website?

The official website for Onconova Therapeutics is www.onconova.com.

Where are Onconova Therapeutics' headquarters?

Onconova Therapeutics is headquartered at 375 PHEASANT RUN, NEWTOWN PA, 18940.

How can I contact Onconova Therapeutics?

Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company can be reached via phone at (267) 759-3680, via email at [email protected], or via fax at 267-759-3681.